仟源医药: 山西仟源医药集团股份有限公司薪酬与考核委员会关于公司2025年限制性股票激励计划（草案）的核查意见

Core Viewpoint - The company has conducted a review of the draft for the 2025 Restricted Stock Incentive Plan and has determined that it meets the necessary legal and regulatory requirements for implementation [1][2][3] Group 1: Eligibility and Compliance - The company is eligible to implement the stock incentive plan as it has not faced any negative audit opinions or internal control issues in the last accounting year [1] - The incentive plan's targets do not include individuals who have been deemed inappropriate candidates by the stock exchange or the China Securities Regulatory Commission (CSRC) in the last 12 months [2] - The plan complies with the relevant laws and regulations, ensuring that the interests of the company and all shareholders are not harmed [2] Group 2: Plan Approval - The Compensation and Assessment Committee unanimously agrees to implement the incentive plan and will submit the related proposals to the company's board of directors for review [3]